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Abstract
Background:
The different operational definitions of breakthrough cancer pain (BTcP) has generated unclear
epidemiological data.
Methods:
A consecutive sample of patients was categorized on the basis of their background pain intensity,
background analgesic treatment, and the presence of BTcP.
Results:
A total of 265 patients were surveyed; 117 patients had background pain and 91 patients presented peaks
of pain intensity distinguishable from background pain. Of 117 patients with background pain, 49 patients
were re-assessed after optimization of background analgesia (T1) within a mean of 8.2 days. Pain intensity
significantly decreased in comparison with values recorded at admission (p50.0005); 75.5% of these
patients had BTcP episodes, with a significant decrease in the number BTcP episodes in comparison with
T0 (p50.0005). The mean BTcP intensity was significantly lower in comparison with T0 (p50.0005).
Finally, the mean duration of untreated BTcP episodes decreased significantly in comparison
with T0 (p¼ 0.016). After optimization of analgesic therapy, most patients with moderate or severe
background pain receiving opioids for moderate pain, patients with moderate or severe pain receiving
strong opioids, and patients with moderate or severe pain receiving no opioids moved to the group of
patients with mild pain receiving strong opioids. The difference was significant (p¼ 0.022).
Conclusion:
Patients having good pain control after optimization of the analgesic regimen may have a decrease
in number, intensity, and duration of BTcP, although the general prevalence of BTcP remains unchanged.
Introduction
Breakthrough cancer pain (BTcP) has been variably reported in literature,
ranging in 40–80% of cancer patients with pain, depending on the setting and
the definition used to identify it1–4. The pioneer definition suggests that ‘‘BTcP
is a transitory increase in pain to greater than moderate intensity which occurs
on a baseline pain of moderate intensity or less’’5. According to a well validated
scoring, this sentence may sound ambiguous, as pain intensity should be severe
(on a numerical scale 7/10), but the baseline pain could be moderate (on a
numerical scale 4–6/10)6. Thus, the differences between the intensity of BTcP
could be minimal (1–2 points on a numerical scale).
This definition was subsequently improved: ‘‘BTcP is a transitory exacerba-
tion of pain that occurs on a background of otherwise stable pain in a patient
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receiving chronic opioid therapy’’5. This sentence intro-
duces a second variable, which is the use of stable doses of
opioids able to maintain baseline pain control, although
this does not mean that baseline pain is effectively con-
trolled, allowing a clear distinction with the peak intensity
of BTcP. This definition also formed the basis for a new,
but similar definition: ‘‘. . . despite relatively stable and
adequately controlled baseline pain’’4,7,8. Other authors
have proposed that BTcP is a transient exacerbation of
pain that occurs irrespective of basal analgesia9, episodes
of pain occurring on an unrealistic pain-free background10,
or ‘‘any transient flare of pain subjectively distinguishable
from an otherwise more or less stable background pain’’11.
In some cases there was no operational definition
a priori, with incident pain due to movement given as
an example, even though patients could have their pain
uncontrolled or were not receiving opioids12. Baseline pain
intensity was severe–maximal in more than half of patients
and, differently from what has been observed by
others12,13, intensity of baseline pain was higher in patients
without BTcP. In other studies most patients had their
pain uncontrolled, were receiving nonopioid analgesics
or weak opioids, or were satisfied with their pain
control13,14,15.
It is difficult to have a clear idea on a complex phenom-
enon without a prospective evaluation and an optimized
analgesic approach. For these reasons it is likely that BTcP
should be more correctly defined as an episode of severe
intensity in patients receiving an adequate treatment with
opioids able to provide at least mild analgesia4,6.
The aim of this study was to characterize BTcP in
advanced cancer patients according to three variables,
including background pain intensity, BTcP intensity,
and analgesic treatment, addressing the hypothesis that
improved background analgesia can modify the preva-
lence, frequency and intensity of BTcP.
Patients and methods
A cohort of cancer patients consecutively admitted to pal-
liative care was surveyed in two home care palliative care
units, FARO foundation (Turin) and L’Aquila per la vita
(L’Aquila), respectively, for a period of 4 months. These
units belong to HOCAI (HomeCare Italy) group and have
a similar profile in terms of assessment and treatment,
providing daily visits or contacts with a complete staff of
physicians, nurses, psychologists, and social workers with
consolidated experience in palliative care and in collect-
ing data for research.
Demographic characteristics were recorded. Patients
were assessed for the presence of background pain and its
intensity in the last 24 hours, as well as the intensity
of BTcP, intended as an episode of severe pain intensity
(7/10) well distinguished from the background
pain intensity. This definition was shared by researchers
in a preliminary investigator meeting. The subgroup of
patients with BTcP due to movement in patients with
bone metastases was also identified. Analgesic treatment
was recorded.
At admission, patients were divided into different cate-
gories, according to the level of background pain intensity
and analgesic drugs used at admission (T0):
(a) Patients with no pain–mild pain without opioids
(b) Patients with mild pain receiving weak opioids
(c) Patients with moderate pain receiving weak opioids
(d) Patients with severe pain receiving weak opioids
(e) Patients with mild pain receiving strong opioids
(f) Patients with moderate pain receiving strong opioids
(g) Patients with severe pain receiving strong opioids
(h) Patients with severe pain, receiving no opioids
(i) Patients with moderate pain, receiving no opioids.
In patients with background analgesia which was con-
sidered inadequate (mainly with a background pain44/10
on a numerical scale 0–10), the same data were collected
after changing the analgesic treatment until a satisfactory
analgesia was achieved (4/10).
Treatment was decided by the responsible physician
from the home care team. The analgesic treatment
consisted of the optimization of opioid doses, eventually
changing opioids, while limiting opioid-related symptoms
with adequate treatment.
Pain and symptom intensity were continuously moni-
tored day-by-day, and treatment changed until the best
balance between analgesia and adverse effects was
achieved. Patients were divided into the same categories
at this time (T1). Other data regarding the characteristics
of BTcP were collected (see appendix for details). Patients
were divided into two groups: advanced cancer patients
receiving chemotherapy, and very advanced cancer
patients no longer receiving chemotherapy (with a sur-
vival of less than 2 months).
Statistics
All continuous data are expressed as mean standard
deviation of the mean. Statistical analysis of quantitative
data, included descriptive statistics, was performed for all
the items. Frequency analysis was performed using
Pearson’s chi-square test and Fisher’s exact test, as
needed. The paired samples Student’s t-test and the
paired Wilcoxon signed-rank test were used to compare
parametric and nonparametric variables, respectively, at
the different intervals. Data were analyzed using Epi Info
software, version 3.2.2 (Centers for Disease Control and
Prevention) and SPSS Software version 14.0 (SPSS Inc.,
Chicago, IL, USA). All p-values were two sided, and
p-values less than 0.05 were considered statistically
significant.
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Results
A total of 267 patients entered the study and 265 patients
were surveyed (two patients were too ill and unable to
participate). The mean age was 67.7 years (SD 14.2),
and 107 (40.4%) were males. Primary tumors were in a
rank order: gastrointestinal (n¼ 64), urogenital (n¼ 48),
lung (n¼ 47), breast (n¼ 45), head and neck (n¼ 17),
liver (n¼ 11), pancreas (n¼ 11), and others (n¼ 22).
The mean Karnofsky performance status was 69.8
(SD 17.4). The flow chart of patients who were surveyed
is presented in Figure 1.
A total of 148 patients had no lasting pain for most
hours of day; 117 patients (44.1%) had background pain
with a mean intensity at admission of 3.6 (SD 2.4); 106
of them (90.6%) were receiving opioids; 91 patients
(77.7%) presented peaks of pain intensity distinguishable
from background pain, and 40 of them (43.9%) had pain
on movement due to bone metastases, interfering with
daily life. The mean pain intensity of these episodes was
8.5 (SD 2.6), the duration of untreated episodes was 28.8
minutes (SD 25.7), and the mean number of episodes
was 2.7/day (SD 1.4). Seventy-three patients (80.2%)
were receiving opioids for BTcP and efficacy was high,
moderate, and poor in 32, 33, and 8 patients, respectively.
Out of 117 patients 49 (53.8%) were considered to have
uncontrolled background pain (mean pain intensity 6.1,
SD 1.6); 37 patients were receiving opioids, and 35 had
episodes distinguished from background analgesia. Of
these, 14 patients had bone pain due to movement.
Twenty-eight patients were receiving BTcP medication.
Twenty-eight patients with BTcP (80%) were prescribed
opioids for BTcP, which were considered to be highly,
moderately, and poorly effective in 7, 17, and 4 patients,
respectively.
In these 49 patients the analgesic treatment or doses of
opioids were changed and a re-assessment was performed
after obtaining adequate background analgesia (T1)
within a mean of 8.2 days (SD 3.7). At T1 the mean
background pain intensity of these 49 patients was 1.9
(SD 1.2), with a significant decrease in pain intensity
in comparison with values recorded at T0 (p50.0005).
Thirty-seven of these patients (75.5 %) had BTcP epi-
sodes, with a significant decrease in the number of BTcP
episodes in comparison with T0 (3.2, SD 1.7, at T0 vs
2.0 0.8 at T1, p50.0005). Fifteen of them (15/37,
40.5%) presented bone pain due to movement, interfering
with daily life in 13 patients. The mean BTcP intensity was
8.0 (SD 1.15), which decreased significantly in compari-
son with T0 (9.0, SD 1.1; p50.0005). Finally, the mean
duration of untreated BTcP episodes was 29 minutes
(SD 23.7), which decreased significantly in comparison
with T0 (39.2, SD 32.2; p¼ 0.016). Thirty-three
patients with BTcP (89.2%) were prescribed opioids for
BTcP, which were considered to be highly, moderately,
and poorly effective in 10, 22, and 1 patients, respectively.
The difference was not significant (p¼ 0.275).
The number of patients belonging to categories A–I
(see methods), and the prevalence of BTcP in these cate-
gories at admission (T0), are presented in Table 1. Data
regarding the 49 patients with uncontrolled pain at admis-
sion (T0) and after optimization of analgesic treatment
49/117 deemed as not controlled background pain
37/49 on opioid therapy (75.5%)
35/49 with BTcP (71.4%)
14/35 with incident pain (40,0%)
28/35 receiving BTcP medication (80,0%)
148 with no pain
117 with pain
2 patients  unavailable
106/117 on opioid therapy (90.6%)
91/117 with BTcP (77.7%)
40/91 with incident pain (43.9%)
73/91 receiving BTcP medication (80.2%)
267 patients screened
68/117  with controlled pain
57/68 on opioid therapy (83.8%) 
54/68 with BTcP (79.4%) 
25/54 with incident pain (46.3%) 
40/54 receiving BTcP medication (74,1%) 
Optimization of background pain
49/49 on opioid therapy (100%)
37/49 with BTcP (75.5%) 
15/37 with incident pain (40.5%) 
33/37 receiving BTcP medication (89,2%) 
117 with controlled pain
106 on opioid therapy (90.5%)
91 with BTcP (77.7%)
40 with incident pain (43.9%)
77 receiving BTcP medication (84.6%)
Figure 1. Study flow chart.
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(T1) in the different categories A–I, and data regarding the
changes of BTcP prevalence between T0 and T1 among
the different categories A–I, are presented in Table 2.
Most patients with BTcP included in categories C and D
(patients with moderate or severe pain receiving opioids
for moderate pain), F and G (patients with moderate or
severe pain receiving strong opioids), H and I (patients
with moderate or severe pain receiving no opioids)
moved to category E (patients with mild pain receiving
strong opioids), after optimizing analgesic treatment. The
difference was significant (p¼ 0.022). No differences
between patients receiving chemotherapy and patients
no longer receiving treatment was observed at either
T0 or T1, p¼ 0.506 and 0.181, respectively.
Discussion
Background pain intensity, background analgesic treat-
ment, and intensity of BTcP have never been concomi-
tantly assessed in epidemiological and clinical studies of
BTcP. In some studies, peaks of pain intensity have been
reported independently on the analgesic treatment, and in
others no clear distinction between background and BTcP
pain intensity has been reported10–14,16,17. We have previ-
ously shown that many studies of BTcP have been per-
formed in patients with uncontrolled background pain.
The gray range of moderate pain (5–6/10) has been indif-
ferently included in the literature as belonging to both
baseline pain or BTcP, and in some cases patients with
severe background pain were included18,19, rendering the
interpretation of data problematic. In most epidemio-
logical surveys, patients not stabilized on adequate opioid
therapy have been considered as patients with BTcP.
Patients with uncontrolled background pain not clearly
distinguished from peaks of pain intensity should be not
considered as ideal for either epidemiological studies or
assessing medication for BTcP. These patients should
also have their pain controlled, which is conventionally
considered to be 4/10 on a numerical scale 0–106,20.
In this study, BTcP prevalence was examined in a global
number of patients who would have been included for the
determination of BTcP and in a subgroup of patients
who, in our opinion, had insufficient background analgesia
and required an optimization of the analgesic treatment.
This approach produced not only an improvement in back-
ground pain intensity, but also a decrease in the number
of episodes/day of BTcP, a decreased intensity and dur-
ation. Patients with moderate (category F) and severe
background pain (category G) receiving opioids moved
to other categories (substantially category E) after opti-
mization of therapy, explaining the improvement in
BTcP characteristics and confirming previous observations
which reported that BTcP may change after 1 week of
opioid titration21,22.
The global prevalence of BTcP, however, did not
change despite optimization of therapy as more than
75% with adequate background pain treated with opioids
may still develop BTcP despite a more moderate presenta-
tion, in terms of number, intensity, and duration.
In a more recent study, the definition included patients
with background pain adequately controlled presenting
episodes of BTcP23. Despite a more strict selection to char-
acterize patients with BTcP, information regarding the
ratio between the presence of pain, the intensity of back-
ground pain and BTcP, as well as pain treatment, was not
shown. Forty-four percent of patients reported BTcP
related to identified factors, 39% had idiopathic BTcP,
and 17% a combination of these. Almost all patients had
mild background pain and severe BTcP pain was reported
in 60% of patients. However, 40% of patients had mild–
moderate BTcP pain, which is not clearly distinguished
from background pain. Moreover, prevalence in the gen-
eral population was not reported4.
The findings of the present study may be limited in
terms of number of patients, especially in the subgroup of
patients requiring optimization of therapy, but has the
Table 2. Data regarding patients with uncontrolled pain at admission (T0)
and after optimization of analgesic treatment, and changes of BTcP
prevalence (p¼ 0.022).
N¼ 49 BTP (n¼ 37, 75.5%)
T0 T1 T0 T1
A 1 1 0 0
B 1 17 1 12
C 8 0 8 0
D 7 1 7 1
E 1 30 1 24
F 12 0 9 0
G 8 0 5 0
H 5 0 3 0
I 6 0 3 0
First columns: Categorization A–I (see text) of the 49 patients with uncon-
trolled pain at admission (T0) and after optimization of analgesic treatment
(T1). Second columns: data regarding the changes in BTcP prevalence
between T0 and T1 among the different categories (p¼ 0.022).
Table 1. Classification of patients according to their pain intensity and
analgesic treatment (see text), and prevalence of BTcP.
N¼ 265 BTcP (n¼ 91)
A 148 (55.8%) 0
B 36 (13.6%) 27
C 8 (3%) 8
D 7 (2.6) 7
E 35 (13.2%) 3
F 12 (4.5%) 10
G 8 (3%) 8
H 5 (1.9%) 0
I 6 (2.3%) 0
Ninety-one of 117of patients with some pain had BTcP (78%).
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advantage of homogeneous and shared protocols of assess-
ment and therapeutic interventions at home, which may
often be lacking in larger multicenter studies.
In conclusion, for a clear interpretation of BTcP, it is
necessary to have well controlled background pain, with
adequate opioid analgesia, and BTcP episodes of a certain
intensity which should be clearly distinguished from back-
ground pain intensity. It has recently been found that
meaningful pain intensity for asking for a BTcP medica-
tion was 7.1, with 77% of patients having a pain intensity
of 7–8 on a numerical scale 0–1024. This aspect has obvious
implications from both the epidemiological and thera-
peutic point of view. An improvement in background
analgesia, however, is unable to limit the global prevalence
of BTcP in advanced cancer patients, but may help
the treatment in terms of number of episodes to treat
and efficacy of BTcP medications. Multicenter studies
with a larger number of patients are necessary to confirm
this preliminary observation.
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